Healthcare News: CMS announces new and revised HCPCS codes for drugs getting pass-through status, PLA drugs, and skin substitutes

Why This Topic Matters

CMS HCPCS updates can affect claim reporting, code maintenance, and compliance for services and products billed after the effective date. Readers who work with drugs, laboratory testing, radiopharmaceuticals, or skin substitute products will want to know which categories were updated and where further review may be needed.

Article Sections

1. CMS Transmittal 11594 and October 1 HCPCS updates

   Overview of the CMS transmittal and the categories of HCPCS changes taking effect October 1. The section frames the article’s focus on laboratory, drug, biologic, radiopharmaceutical, and skin substitute updates.

2. New PLA HCPCS codes

   Discussion of newly announced proprietary laboratory analysis codes and the general testing areas they address. The section identifies the range of PLA-related updates included in the transmittal.

3. New HCPCS codes for drugs with pass-through status

   Summary of newly added HCPCS identifiers associated with drugs receiving pass-through status. The section places these code additions in the context of the October effective date.

4. Revised HCPCS codes for drugs, biologics, and radiopharmaceuticals

   Coverage of updated HCPCS entries for several therapeutic and diagnostic products. The section also notes that the article distinguishes these revisions from the newly added codes.

5. New skin substitute HCPCS codes and descriptor change

   Explanation of new skin substitute product codes and a separate descriptor update for another skin substitute code. The section also notes the article’s mention of cost-related classification for a subset of the new products.